Preventing the misfolding, aggregation, accumulation and propagation of α-synuclein — pivotal mechanisms that contribute to neurodegeneration in Parkinson disease (PD) and other synucleinopathies — is the ultimate goal of research into neuroprotective therapy. Now, exenatide, a glucagon-like peptide-1 (GLP-1) agonist, has been reported to ameliorate the severity of motor symptoms associated with PD.
Refers to Athauda, D. et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancethttp://dx.doi.org/10.1016/S0140-6736(17)31585-4 (2017)